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expression was assessed by immunohistochemistry (Dako 
PD-L1 IHC 73-10 pharmDx).
Results A total of 168 patients with MBC, including 58 
patients with triple-negative breast cancer (TNBC), were 
treated with avelumab for 2–50 weeks and followed for 
6–15 months. Patients were heavily pretreated with a median 
of three prior therapies for metastatic or locally advanced 
disease. Grade ≥ 3 treatment-related AEs occurred in 13.7% 
of patients, including two treatment-related deaths. The con-
firmed objective response rate (ORR) was 3.0% overall (one 
complete response and four partial responses) and 5.2% in 
patients with TNBC. A trend toward a higher ORR was seen 
Abstract 
Purpose Agents targeting programmed death receptor 1 
(PD-1) or its ligand (PD-L1) have shown antitumor activity 
in the treatment of metastatic breast cancer (MBC). The aim 
of this study was to assess the activity of avelumab, a PD-L1 
inhibitor, in patients with MBC.
Methods In a phase 1 trial (JAVELIN Solid Tumor; 
NCT01772004), patients with MBC refractory to or pro-
gressing after standard-of-care therapy received avelumab 
intravenously 10  mg/kg every 2  weeks. Tumors were 
assessed every 6 weeks by RECIST v1.1. Adverse events 
(AEs) were graded by NCI-CTCAE v4.0. Membrane PD-L1 
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in patients with PD-L1+ versus PD-L1− tumor-associated 
immune cells in the overall population (16.7% vs. 1.6%) and 
in the TNBC subgroup (22.2% vs. 2.6%).
Conclusion Avelumab showed an acceptable safety pro-
file and clinical activity in a subset of patients with MBC. 
PD-L1 expression in tumor-associated immune cells may be 
associated with a higher probability of clinical response to 
avelumab in MBC.
Keywords Avelumab · Metastatic breast cancer · Triple-
negative breast cancer · PD-L1 · Second-line
Introduction
Despite advances in the treatment of breast cancer and 
an encouraging 5-year overall survival rate of approxi-
mately 90% in the United States, up to 30% of patients 
with an early-stage diagnosis eventually progress to incur-
able metastatic disease, and 6% of patients have metastatic 
disease at diagnosis [1, 2]. Treatment of metastatic breast 
cancer (MBC) is based on molecular subtype and may 
include chemotherapy, human epidermal growth factor 
receptor 2 (HER2)-directed agents, and endocrine-based 
therapies or agents targeted to mechanistic target of rapa-
mycin or CDK4/6 for those tumors overexpressing estro-
gen receptor (ER) and/or progesterone receptor (PR) [3]. 
Approximately, 15–20% of patients have breast cancers 
lacking expression of ER, PR, or HER2, which are termed 
triple-negative breast cancer (TNBC). For these patients, 
standard treatment is cytotoxic chemotherapy, which is 
limited by poor tolerability and short duration of response 
[4–6]. Thus, new therapies are needed for patients with 
MBC whose disease has progressed following standard 
therapies.
Immune checkpoint inhibitors, particularly agents tar-
geting programmed death receptor 1 (PD-1) or its ligand 
(PD-L1), are being increasingly explored as a potential 
treatment strategy in various cancers [7]. Breast can-
cers express PD-L1, with higher expression often seen 
in TNBC tumors [8–10]. Binding of PD-L1 to its recep-
tor on T cells, PD-1, inhibits adaptive immune responses 
in the tumor microenvironment, which enables tumor 
cell escape from immune cells [11–13]. The presence of 
tumor-infiltrating lymphocytes (TILs) in breast cancer has 
been shown to have a strong prognostic association [14]. 
High TIL levels are associated with tumors having PD-L1 
expression, and PD-L1+ tumors with high TILs have bet-
ter outcomes [9, 10, 15]. PD-L1 expression may serve as a 
marker of immune activity, and local immunosuppression 
of TILs via the PD-L1/PD-1 pathway may be an important 
means of tumor immune evasion [8, 14]. Inhibition of the 
PD-L1/PD-1 axis with monoclonal antibodies may be one 
means of restoring immune surveillance and cell-mediated 
antitumor activity, and studies of anti-PD-L1/PD-1 agents 
have shown durable antitumor responses in patients with 
various advanced cancers [7, 16]. Early-phase studies 
have suggested that these agents may also have clinical 
activity in breast cancer, particularly in the TNBC subtype 
[17–19].
Avelumab (MSB0010718C) is a human anti-PD-L1 
IgG1 monoclonal antibody that inhibits the interaction 
between PD-1 and PD-L1, leaving PD-1/PD-L2 interac-
tions intact [20]. Unlike other anti-PD-L1/PD-1 antibodies 
approved or in advanced clinical development, avelumab 
has been shown to induce antibody-dependent cell-medi-
ated cytotoxicity (ADCC) of tumor cells in preclinical 
studies, suggesting it may potentially have an additional 
mechanism of action [21–23]. In phases 1 and 2 clinical 
studies, avelumab has been well tolerated and associated 
with durable responses in patients with various advanced 
tumors, including Merkel cell carcinoma (MCC), non-
small cell lung cancer, and urothelial carcinoma [20, 
24–26]. Avelumab is approved by the US Food and Drug 
Administration for the treatment of metastatic MCC 
and locally advanced or metastatic urothelial carcinoma 
that has progressed during or after platinum-containing 
chemotherapy [27]. In the phase 1a part of the JAVELIN 
Solid Tumor study, avelumab was safely administered by 
intravenous infusion every 2 weeks and had a predictable 
pharmacokinetic profile at doses of up to 20 mg/kg; the 
10 mg/kg dose was selected for further study in phase 1b 
dose-expansion cohorts enrolling a range of tumor types 
[20]. Here, we report the evaluation of avelumab in a phase 
1b cohort of patients with MBC as part of the JAVELIN 
Solid Tumor trial.
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JAVELIN Solid Tumor is an international, open-label, phase 
1 trial in patients with advanced solid malignancies. In the 
dose-expansion cohort reported here, eligible patients had 
histologically confirmed locally advanced or MBC that was 
refractory to or had progressed after standard-of-care ther-
apy. Eligible patients were aged ≥ 18 years and had an East-
ern Cooperative Oncology Group (ECOG) performance sta-
tus of 0 or 1, an estimated life expectancy of > 3 months, and 
adequate hepatic, renal, and hematologic function. Patients 
had received ≤ 3 prior lines of cytotoxic therapy (excluding 
systemic therapy that was not considered cytotoxic) and, 
unless contraindicated, were required to have received prior 
treatment with a taxane and anthracycline in any therapeutic 
setting. Patients had ≥ 1 measurable lesion per Response 
Evaluation Criteria In Solid Tumors (RECIST) version 1.1 
[28]. A biopsy or surgical specimen for biomarker testing 
collected within 90 days prior to the first avelumab admin-
istration was required. Patients were unselected for PD-L1 
expression and breast cancer subtype. Patients were enrolled 
in accordance with an approved protocol, international 
standards of good clinical practice, and institutional safety 
monitoring, and written informed consent was provided by 
patients.
Procedures and assessments
Patients received avelumab (EMD Serono, Research & 
Development Institute, Billerica, MD, USA, a business of 
Merck KGaA, Darmstadt, Germany) 10 mg/kg intravenously 
every 2 weeks until confirmed disease progression, unac-
ceptable toxicity, or other protocol-based criteria for with-
drawal occurred. Safety and tolerability were assessed per 
the National Cancer Institute’s Common Terminology Crite-
ria for Adverse Events (NCI-CTCAE), version 4.0. Potential 
immune-related adverse events (AEs) were identified using a 
prespecified list of Medical Dictionary for Regulatory Activ-
ities terms. Signs and symptoms of an infusion-related reac-
tion, such as fever, chills, or rigors reported on the same day 
or the day following treatment, were queried with investiga-
tors to ascertain whether an AE of infusion-related reaction 
should be recorded. Premedication with diphenhydramine 
and acetaminophen was required 30–60 min before all infu-
sions of avelumab to mitigate the occurrence of infusion-
related reactions. Tumors were evaluated radiographically 
at baseline and every 6 weeks for the first 12 months, then 
every 12 weeks thereafter. Best overall response, duration 
of response, and progression-free survival were determined 
according to RECIST version 1.1 per investigator.
HER2, ER, and PR statuses were obtained from patient 
records. Levels of PD-L1 protein expressed on tumor cell 
membranes and on membranes and/or cytoplasm of immune 
cells within the tumor microenvironment were assessed by 
immunohistochemistry (IHC) staining of formalin-fixed, 
paraffin-embedded tissue sections of the most recent suit-
able biopsy or surgical specimen using a proprietary assay 
(PD-L1 IHC 73-10 pharmDx; Dako, Carpinteria, CA, USA) 
with an anti-PD-L1 rabbit monoclonal antibody. PD-L1 
expression was assessed prospectively by central independ-
ent reviewers, who were blinded to any clinical data; expres-
sion was based on the percentages of tumor cells expressing 
PD-L1: 1 and 5% thresholds with any staining intensity and a 
25% threshold with moderate to high staining. Additionally, 
dense aggregates of tumor-associated immune cells (identi-
fied as nonmalignant cells based on morphology) adjacent 
to tumor cells were assayed using a defined threshold of 10% 
of immune cells expressing PD-L1 at any staining intensity.
Statistical methods
Enrollment of approximately 150 patients was planned for 
this cohort, and safety and activity were analyzed in all 
patients who received ≥ 1 dose of avelumab. The prespeci-
fied primary analysis occurred 6 months after the date of the 
first dose in the last patient enrolled. The objective response 
rate (ORR), defined as the proportion of patients with a 
confirmed best response of complete or partial response, 
was calculated with corresponding Clopper–Pearson CIs. 
Time-to-event endpoints (duration of response, progression-
free survival, and overall survival) were estimated using 
Kaplan–Meier method, and CIs for the median were deter-
mined using the Brookmeyer–Crowley method. The trial is 
registered with ClinicalTrials.gov as NCT01772004.
Results
Patients
Of 266 patients screened, 168 patients with histologically 
confirmed MBC refractory to or progressing after standard-
of-care therapy were enrolled and treated with avelumab 
between November 2013 and February 2015 (Table  1, 
Appendix Tables 4, 5). Of these 168 patients, 26 patients 
(15.5%) had HER2-positive disease (irrespective of ER and 
PR status), 72 patients (42.9%) had hormone-receptor-pos-
itive/HER2-negative disease, and 58 patients (34.5%) had 
TNBC. Median age was 55 (range 31–81) years. Patients 
had received a median of three prior therapies for meta-
static disease, and 123 patients (73.2%) had received ≥ 2 
prior anticancer regimens for metastatic or locally advanced 
disease (Table 1; Appendix Tables 4, 6). Median time since 
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Table 1  Selected baseline characteristics
ECOG PS Eastern Cooperative Oncology Group performance status, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, 
PD-L1 programmed death-ligand 1, PR progesterone receptor, TNBC triple-negative breast cancer
a Patients who were uncoded (overall, 41; TNBC, 11), other histology (overall, 10; TNBC, 5), or missing (overall, 3)
b Unknown molecular subtype was due to incomplete information in the medical records database (ER/PR status known, but HER2 status 
Characteristics Total population N = 168 TNBC subgroup (n = 58)
Median age, years (range) 55 (31–81) 52.5 (31–80)
Age category, n (%) (years)
 < 65 140 (83.3) 54 (93.1)
 ≥ 65 28 (16.7) 4 (6.9)
Sex, n (%)
 Male 1 (0.6) 0
 Female 167 (99.4) 58 (100)
Race or ethnic group, n (%)
 White 143 (85.1) 45 (7.8)
 Black or African American 16 (9.5) 9 (15.5)
 Asian 3 (1.8) 1 (1.7)
 Other 6 (3.6) 3 (5.2)
Geographic region, n (%)
 United States 112 (66.7) 48 (82.8)
 Europe 56 (33.3) 10 (17.2)
ECOG PS, n (%)
 0 83 (49.4) 33 (56.9)
 1 85 (50.6) 25 (43.1)
Smoking history, n (%)
 Never smoker 107 (63.7) 36 (62.1)
 Current or former smoker 50 (29.8) 17 (29.3)
 Unknown 11 (6.5) 5 (8.6)
Histological subtype of tumor, n (%)
 Ductal 94 (56.0) 36 (62.1)
 Lobular 6 (3.6) 0
 Carcinoma, not otherwise specified 14 (8.3) 6 (10.3)
 Othera 54 (32.1) 16 (27.6)
Molecular subtype, n (%)
 TNBC 58 (34.5) 58 (100)
 HER2−/ER+ or PR+ 72 (42.9) –
 HER2+ 26 (15.5) –
 Unknownb 12 (7.1) –
Median time since first diagnosis, months (range) 53.5 (7.3–407.5) 40.3 (7.3–241.0)
Median time since diagnosis of metastatic disease, months (range)c 21.6 (0.7–176.8) 13.2 (0.7–176.8)
Prior anticancer lines of therapy for metastatic or locally advanced disease, n 
(%)d
 ≤ 1 45 (26.8) 29 (50.0)
 2 35 (20.8) 16 (27.6)
 ≥ 3 88 (52.4) 13 (22.4)
 Median (range) 3 (0–10) 2 (1–6)
PD-L1 expression status, n/N (%)e PD-L1+ PD-L1− PD-L1+ PD-L1−
≥ 1% tumor cells 85/136 (62.5) 51/136 (37.5) 33/48 (68.8) 15/48 (31.2)
≥ 5% tumor cells 23/136 (16.9) 113/136 (83.1) 13/48 (27.1) 35/48 (72.9)
≥ 25% tumor cells 3/136 (2.2) 133/136 (97.8) 2/48 (4.2) 46/48 (95.8)
≥ 10% tumor-associated immune cells 12/136 (8.8) 124/136 (91.2) 9/48 (18.8) 39/48 (81.2)
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diagnosis of metastatic disease was 22  months (range 
3 weeks to > 14.7 years). Of 58 patients with TNBC, 50% 
had received ≥ 2 prior lines of therapy for metastatic dis-
ease and median time since diagnosis was 13 months. Tumor 
specimens were evaluable for PD-L1 expression in 136 
patients (81.0%), and based on a threshold of ≥ 1% tumor 
cell staining, 85 of 136 (62.5%) had PD-L1+ tumors. Using 
a ≥ 10% threshold for PD-L1 expression in tumor-associ-
ated immune cells, 12 of 136 evaluable patients (8.8%) had 
PD-L1+ tumors.
At the time of data cutoff (February 27, 2015), patients 
had received a median of four avelumab (range 1–23) doses 
and had a median treatment duration of 8.0 (range 2–50) 
weeks. Median duration of follow-up was 10.0 (range 
6.0–15.2) months, and nine patients (5.4%) remained on ave-
lumab treatment at data cutoff. Disease progression was the 
most common reason for treatment discontinuation (74.4%).
Safety
Treatment-related AEs of any grade occurred in 115 patients 
(68.5%), including a grade ≥ 3 event in 23 patients (13.7%; 
Table 2; Appendix Table 7). The most commonly occur-
ring treatment-related AEs of any grade (> 10% of patients) 
were fatigue (19.0%), infusion-related reaction (14.3%), and 
nausea (13.1%). Treatment-related AEs of any grade clas-
sified as immune-related occurred in 17 patients (10.1%): 
hypothyroidism (4.8%), autoimmune hepatitis and pneumo-
nitis (1.8% each), thrombocytopenia (1.2%), and antinuclear 
antibody production, dry eye, elevated rheumatoid factor, 
hyperthyroidism, and pemphigoid skin reaction (0.6% each; 
Appendix Table 8). Four patients (2.4%) had a grade ≥ 3 
immune-related, treatment-related AE (Appendix Table 8), 
including three patients (1.8%) with grade 3 autoimmune 
hepatitis and one patient each with grade 3 pneumonitis and 
grade 4 thrombocytopenia (0.6% each). One patient with 
autoimmune hepatitis who had progressive liver metastasis 
died of acute liver failure.
Of eight patients (4.8%) who discontinued avelumab 
because of a treatment-related AE, three (1.8%) discontin-
ued because of an immune-related AE (autoimmune hepa-
titis [n = 2, both grade 3] and pemphigoid [n = 1, grade 
2]); other treatment-related AEs resulting in discontinua-
tion were elevated γ-glutamyl transferase (n = 2, grades 3 
and 4), elevated aspartate aminotransferase (n = 1, grade 
3), elevated creatine phosphokinase (n = 1, grade 1), and 
respiratory distress (n = 1, grade 5). Two patients (1.2%) had 
a treatment-related death, including the patient with acute 
liver failure described above and a patient with metastatic 
lesions of liver, lung, and soft tissues and a history of respir-
atory disorders (cough, dyspnea, and pneumonia) who died 
of respiratory distress. The patient with treatment-related 
respiratory distress also presented with unspecified sepsis, 
most likely secondary to healthcare-associated pneumonia, 
and extensive pulmonary metastasis.
Antitumor activity
Based on investigator assessment, five patients had a con-
firmed objective response, including one complete response 
and four partial responses, resulting in a confirmed ORR 
of 3.0% (95% CI 1.0–6.8; Table 3). Notably, three of five 
confirmed responders (60.0%) had TNBC, resulting in an 
ORR of 5.2% in this subset (Appendix Table 9). The other 
two confirmed responders had HER2− ER/PR+ disease, 
and the ORR in this subset was 2.8% (Appendix Table 9). 
Four out of five responses were ongoing at data cutoff, and 
median duration of response was not reached (95% CI 28.7, 
ne). The unconfirmed ORR in the total population was 
4.8%, including one complete response and seven partial 
responses, and the median time to response was 11.4 weeks 
(range 5.7–17.6 weeks) (Fig. 1). Stable disease was the best 
response in 42 patients (25.0%), and the disease control rate 
(DCR)—based on patients with a confirmed response or sta-
ble disease—was 28.0% (47 of 168) (Table 3). Within the 
TNBC subgroup, 15 patients (25.9%) had stable disease as 
best response, and the DCR was 31.0% (18 of 58). Of the 47 
patients with a best response of complete response, partial 
response, or stable disease, 14 (29.8%) remained progression 
free for ≥ 24 weeks.
Of 140 patients who had evaluable data for sum of tar-
get lesion diameter at baseline and on study, 39 patients 
(27.9%) experienced tumor shrinkage of any level. Sixteen 
(11.4%) of these patients had tumor shrinkage of ≥ 30%, 
unknown in four patients) or to information collected retrospectively (molecular subtype status was from post-baseline samples in eight patients 
and therefore was not used for baseline characterization)
c Time since diagnosis of metastatic disease was missing for eight patients in the overall study population and six patients in the TNBC subgroup
d Regimen for metastatic disease may have included hormonal therapy, either alone or in combination with chemotherapy. Systemic therapies that 
were not necessarily cytotoxic are included in the number of prior regimens reported here, but the number of prior cytotoxic therapies permitted 
was ≤ 3
e Non-evaluable specimens included those that were missing, of poor quality or quantity (insufficient tissue on slide or insufficient tumor sample), 
or otherwise not available to provide results; all biopsy or surgical specimens were required to be collected within 90 days of first administration 
of avelumab
Table 1  (continued)
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including two patients with progressive disease by 
RECIST who had a partial response by modified immune-
related response criteria (Fig. 2). Among 46 evaluable 
patients with TNBC, 21 (45.7%) had tumor shrinkage of 
any level, which was by ≥ 30% in ten patients (21.7%) 
(Fig. 3).
No trends for response were observed based on patient 
or disease characteristics, including age, race, ECOG sta-
tus, and prior lines of therapy (Appendix Table 9). In addi-
tion, no efficacy trends were seen in subgroups defined by 
PD-L1 expression in tumor cells at different thresholds 
(Appendix Table 10). However, in evaluable patients with 
PD-L1+ or PD-L1− tumor-associated immune cells (10% 
staining cutoff), the ORR was 16.7% (2 of 12 patients) 
versus 1.6% (2 of 124 patients) in the overall group, and 
22.2% (2 of 9 patients) versus 2.6% (1 of 39 patients) in 
patients with TNBC.
Discussion
In this study of 168 heavily pretreated patients with MBC 
refractory to or progressing after standard-of-care therapy, 
avelumab monotherapy showed an acceptable safety profile 
with an incidence of grade ≥ 3 treatment-related AEs (13.7%) 
comparable with other anti-PD-L1/PD-1 therapies in MBC 
[17, 18]. Antitumor activity was modest, with a confirmed 
ORR of 3.0% based on one complete response and four partial 
responses. Of these five responders, three were in the TNBC 
subgroup (ORR 5.2%). Importantly, responses were durable, 
and the median duration of response was not reached during 
available follow-up. Tumor shrinkage occurred in 27.9% of 
evaluable patients in the overall MBC group and in 45.7% of 
patients with TNBC. The DCR was 28.0% in the total patient 
group and 31.0% in patients with TNBC. Preclinical stud-
ies suggest that avelumab may mediate tumor lysis through 
Table 2  Treatment-related 
adverse events occurring at any 
grade in ≥ 5% of patients or 
grade ≥ 3 in any patient
ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transferase
N = 168 Any grade Grades 1–2 Grade 3 Grade 4 Grade 5
Any event, n (%) 115 (68.5) 92 (54.8) 16 (9.5) 5 (3.0) 2 (1.2)
 Fatigue 32.9 (19.0) 29 (17.3) 3 (1.8) 0 0
 Infusion-related reaction 24 (14.3) 24 (14.3) 0 0 0
 Nausea 22 (13.1) 22 (13.1) 0 0 0
 Diarrhea 15 (8.9) 15 (8.9) 0 0 0
 Arthralgia 13 (7.7) 12 (7.1) 1 (0.6) 0 0
 Decreased appetite 12 (7.1) 12 (7.1) 0 0 0
 Influenza-like illness 11 (6.5) 11 (6.5) 0 0 0
 Dyspnea exertional 5 (3.0) 4 (2.4) 1 (0.6) 0 0
 Elevated AST 4 (2.4) 3 (1.8) 1 (0.6) 0 0
 Elevated GGT 4 (2.4) 1 (0.6) 1 (0.6) 2 (1.2) 0
 Anemia 3 (1.8) 0 2 (1.2) 1 (0.6) 0
 Autoimmune hepatitis 3 (1.8) 0 3 (1.8) 0 0
 Elevated ALT 3 (1.8) 2 (1.2) 1 (0.6) 0 0
 Hypoxia 3 (1.8) 2 (1.2) 1 (0.6) 0 0
 Pneumonitis 3 (1.8) 2 (1.2) 1 (0.6) 0 0
 Axillary pain 2 (1.2) 1 (0.6) 1 (0.6) 0 0
 Thrombocytopenia 2 (1.2) 1 (0.6) 0 1 (0.6) 0
 Acute hepatic failure 1 (0.6) 0 0 0 1 (0.6)
 Cardiac arrest 1 (0.6) 0 0 1 (0.6) 0
 Hypertriglyceridemia 1 (0.6) 0 1 (0.6) 0 0
 Hypokalemia 1 (0.6) 0 0 1 (0.6) 0
 Neutropenia 1 (0.6) 0 0 1 (0.6) 0
 Neutrophil count decreased 1 (0.6) 0 1 (0.6) 0 0
 Noncardiac chest pain 1 (0.6) 0 1 (0.6) 0 0
 Pleuritic pain 1 (0.6) 0 1 (0.6) 0 0
 Proteinuria 1 (0.6) 0 1 (0.6) 0 0
 Pulmonary arterial hypertension 1 (0.6) 0 1 (0.6) 0 0
 Respiratory distress 1 (0.6) 0 0 0 1 (0.6)
 Respiratory failure 1 (0.6) 0 0 1 (0.6) 0
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ADCC, indicating the presence of a potential second mecha-
nism of action [21–23]. However, no clinical data are avail-
able to show that ADCC contributes to the clinical activity of 
avelumab. Importantly, the frequency of immune cell subsets 
is not decreased following treatment with avelumab [29].
To date, the use of PD-L1 as a predictive biomarker for 
MBC remains controversial given the use of different PD-L1 
antibodies and detection assays, various PD-L1 expression 
cutoffs, and non-standardized test designs [30, 31]. Stud-
ies of pembrolizumab (anti-PD-1) and atezolizumab (anti-
PD-L1) have included analyses of tumor PD-L1 expression 
in patients with TNBC [17, 19]. In the phase 1b KEY-
NOTE-012 study of pembrolizumab in PD-L1+ TNBC 
(n = 27 evaluable patients), PD-L1 positivity was defined 
as expression in the stroma or in ≥ 1% of tumor cells based 
on IHC staining using the 22C3 PD-L1 antibody. In this 
PD-L1+ cohort, the ORR was 18.5%, 37.5% of evaluable 
patients had tumor shrinkage of any level, and the DCR 
was 25.9% [17]. An exploratory analysis suggested an asso-
ciation between PD-L1 score (percentage of inflammatory 
and tumor cells staining for PD-L1) and the probability 
of response and progression-free survival with pembroli-
zumab. Similarly, in a phase 1a study of atezolizumab in 
115 patients with heavily pretreated TNBC, of whom 71 
were PD-L1+ (based on ≥ 5% of tumor-infiltrating immune 
cells [IHC score of 2/3 using the SP142 assay]) and were 
Table 3  Antitumor activity of avelumab
Treatment responses are based on confirmed response according per Response Criterion In Solid Tumors version 1.1
DCR disease control rate (defined as responses + stable disease), ne not estimable, ORR objective response rate
a Stable disease at the first post-baseline tumor assessment after 6 weeks was required to qualify for a best response of SD
b Includes “missing” and “not assessable”
Study population N = 168 TNBC subgroup n = 58
Complete response, n (%) 1 (0.6) 0
Partial response, n (%) 4 (2.4) 3 (5.2)
Stable disease,a n (%) 42 (25.0) 15 (25.9)
Progressive disease, n (%) 106 (63.1) 38 (65.5)
Nonevaluable,b n (%) 15 (8.9) 2 (3.4)
ORR (95% CI) (%) 3.0 (1.0 to 6.8) 5.2 (1.1 to 14.4)
DCR (%) 28.0 31.0
Median (95% CI) duration of response in confirmed responders (weeks) ne (28.7 to ne) ne (ne to ne)
Median (95% CI) progression-free survival (weeks) 5.9 (5.9 to 6.0) 5.9 (5.7 to 6.9)
Progression-free survival rate at 24 weeks (95% CI) (%) 10.1 (5.9 to15.5) 12.4 (5.2 to 22.8)
Median (95% CI) overall survival (months) 8.1 (6.4 to ne) 9.2 (4.3 to ne)
Overall survival rate at 12 months (95% CI) (%) 40.3 (29.6 to 50.7) 37.1 (18.3 to 56.2)
Fig. 1  Time to and duration of response for patients with confirmed or unconfirmed responses
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considered evaluable for efficacy, the unconfirmed ORR was 
13% [19]. In our study, a possible trend toward a higher ORR 
was seen in patients with PD-L1+ versus PD-L1− tumor-
associated immune cells, both in the overall population 
(16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 
2.6%). The response rate to avelumab in patients with 
TNBC and PD-L1+ tumor-associated immune cells is com-
parable with the response rate of 18.5 and 13% reported 
for patients with PD-L1+ TNBC treated with pembroli-
zumab and atezolizumab, respectively [17, 19]. Although 
the small number of evaluable patients with PD-L1+ TILs 
in our study (n = 12) precludes any definitive conclusions, 
these data support the hypothesis that PD-L1 expression on 
TILs may predict response to checkpoint inhibitor therapy 
in breast cancer. In our study, unlike in the pembrolizumab 
and atezolizumab studies, PD-L1 expression was evaluated 
Fig. 2  Best change in target lesions from baseline in 140 evaluable patients with baseline tumor assessment and ≥ 1 post-baseline assessment
Fig. 3  Percent change in target lesions from baseline in 46 evaluable patients with TNBC with baseline tumor assessment and ≥ 1 post-baseline 
assessment
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separately in tumor cells and tumor-associated immune cells 
as prespecified in the analysis plan, and the Dako PD-L1 IHC 
73-10 pharmDx assay was used for the evaluation. Efforts 
to standardize testing for PD-L1 expression are underway, 
including the Blueprint PD-L1 IHC comparison project [32]. 
Data are not yet available to compare the performance of the 
73-10 assay with that of other assays, although studies are 
ongoing, and the 73-10 assay will be included in phase 2 of 
the Blueprint study. Studies to characterize the potential of 
PD-L1 as a predictive biomarker for avelumab are ongoing.
In conclusion, our data show that the anti-PD-L1 anti-
body avelumab has a safety profile that is considered gener-
ally manageable and tolerable, and showed modest clinical 
activity in a heavily pretreated population of patients with 
MBC. Collectively, our findings and those of other studies 
suggest that durable clinical benefit can be achieved with 
anti-PD-1/PD-L1 monotherapy in a subset of patients with 
MBC, particularly TNBC [17–19]. Based on the results from 
single-agent immunotherapy in patients with MBC, studies 
of combination therapy that might increase the probability 
of treatment benefit are warranted, and promising clinical 
activity in TNBC has been reported for a treatment regimen 
of atezolizumab administered in combination with taxane 
chemotherapy (NCT01633970) and of pembrolizumab in 
combination with eribulin mesylate (NCT02513472) in 
preliminary studies [33, 34]. An ongoing phase 1b/2 study 
(JAVELIN Medley; NCT02554812), which includes a 
TNBC cohort, is currently assessing avelumab in combina-
tion with novel immunotherapies.
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Appendix
See Tables 4, 5, 6, 7, 8, 9, and 10.
Table 4  Additional patient demographics and disease characteristics
Characteristics, n (%) N = 168
Prior surgery 161 (95.8)
Prior radiotherapy 139 (82.7)




Median (range) 4.0 (1–10)
Prior platinum regimen
 Carboplatin based 36 (21.4)
 Cisplatin based 9 (5.4)
Type of prior anticancer therapy
 Chemotherapy 168 (100.0)
 Hormonal therapy 103 (61.3)
 Antibody therapy 30 (17.9)
 Kinase inhibitor 19 (11.3)
 Vaccines 1 (0.6)
 Other 36 (21.4)




 Locally advanced 30 (17.9)
 Palliative 7 (4.2)
Best response to any prior anticancer therapy
 Complete response 3 (1.8)
 Partial response 9 (5.4)
 Stable disease 33 (9.6)
 Progressive disease 94 (56.0)
 Not assessable 1 (0.6)
 Unknown 13 (7.7)
 Not applicable 15 (8.9)
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Table 5  Key eligibility criteria
ECOG Eastern Cooperative Oncology Group, MBC metastatic breast cancer, PD-L1 programmed death-ligand 1, RECIST Response Evaluation 
Criteria In Solid Tumors
Inclusion criteria Exclusion criteria
Age ≥ 18 years Prior therapy with any drug targeting T cell coregulatory proteins
Histologically confirmed MBC that is refractory to or progressive after 
standard-of-care therapy
Concurrent anticancer therapy within 4 weeks of start of trial treatment, 
use of hormonal agents within 7 days of start of trial treatment, or any 
other concurrent investigational treatment
No more than three prior lines of cytotoxic therapy for metastatic 
disease
Prior treatment with immunosuppressive agents such as steroids
Prior treatment with a taxane and an anthracycline, unless contraindi-
cated
Major surgery ≤ 4 weeks prior to enrollment
Availability of a formalin-fixed, paraffin-embedded block containing 
tumor tissue or unstained tumor slides suitable for PD-L1 expression 
assessment
Previous malignant disease other than MBC within the last 5 years 
except for basal or squamous cell carcinoma of the skin or cervical 
carcinoma in situ
ECOG performance status score of 0 or 1 Metastases of the central nervous system
Measurable disease by RECIST version 1.1 or objective evidence of 
disease without a measurable lesion
Clinically significant illness, including infection, autoimmune disease 
(other than diabetes mellitus type 1, vitiligo, psoriasis, hypothyroid 
disease, or hyperthyroid disease not requiring immunosuppressive 
treatment), cardiovascular disease, or a psychiatric condition affecting 
the understanding or rendering of informed consent
Estimated life expectancy of ≥ 3 months Persisting toxicity of grade > 1 related to prior therapy (except 
grade ≤ 2 sensory neuropathy)
Adequate renal, hepatic, and hematologic function Known severe hypersensitivity to monoclonal antibodies, history of 
anaphylaxis, or uncontrolled asthma
Use of highly effective contraception Vaccination (other than inactivated vaccines) within 55 days of the first 
dose of avelumab
Signed written informed consent Pregnancy or lactation
Known alcohol or drug abuse
Legal incapacity or limited legal capacity
















Gemcitabine hydrochloride 17 (10.1)
Eribulin 16 (9.5)
Pegylated liposomal doxorubicin hydrochloride 16 (9.5)
Methotrexate 12 (7.1)
Vinorelbine tartrate 10 (6.0)
Cyclophosphamide with doxorubicin 9 (5.4)
Lapatinib 7 (4.2)
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Table 7  Adverse events 
(related or unrelated) of any 
grade in > 5% of patients or of 
grade ≥ 3 in any patient
Adverse event, n (%) Patients (N = 168)
Any grade Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Any event, n (%) 161 (95.8) 24 (14.3) 57 (33.9) 48 (28.6) 10 (6.0) 22 (13.1)
Fatigue 63 (37.5) 30 (17.9) 30 (17.9) 3 (1.8) 0 0
Nausea 49 (29.2) 29 (17.3) 19 (11.3) 1 (0.6) 0 0
Constipation 29 (17.3) 21 (12.5) 8 (4.8) 0 0 0
Decreased appetite 29 (17.3) 19 (11.3) 10 (6.0) 0 0 0
Diarrhea 29 (17.3) 22 (13.1) 7 (4.2) 0 0 0
Vomiting 25 (29.2) 14 (8.3) 9 (5.4) 2 (1.2) 0 0
Back pain 24 (14.3) 10 (6.0) 7 (4.2) 7 (4.2) 0 0
Cough 24 (14.3) 19 (11.3) 5 (3.0) 0 0 0
Dyspnea 24 (14.3) 10 (6.0) 4 (2.4) 9 (5.4) 1 (0.6) 0
Infusion-related reaction 24 (14.3) 6 (3.6) 18 (10.7) 0 0 0
Arthralgia 23 (13.7) 15 (8.9) 3 (1.8) 5 (3.0) 0 0
Dyspnea exertional 23 (13.7) 15 (8.9) 6 (3.6) 1 (0.6) 1 (0.6) 0
Pyrexia 21 (12.5) 18 (10.7) 2 (1.2) 1 (0.6) 0 0
Abdominal pain 19 (11.3) 11 (6.5) 5 (3.0) 3 (1.8) 0 0
Abdominal pain upper 19 (11.3) 7 (4.2) 11 (6.5) 1 (0.6) 0 0
Anemia 17 (10.1) 2 (1.2) 5 (3.0) 9 (5.4) 1 (0.6) 0
Pleural effusion 17 (10.1) 4 (2.4) 4 (2.4) 8 (4.8) 1 (0.6) 0
Urinary tract infection 17 (10.1) 5 (3.0) 12 (7.1) 0 0 0
Asthenia 16 (9.5) 7 (4.2) 6 (3.6) 3 (1.8) 0 0
Table 6  (continued) Therapy Patients (N = 168)
Pertuzumab 7 (4.2)
Cisplatin 6 (3.6)
Trastuzumab emtansine 6 (3.6)
Vinorelbine 6 (3.6)
Eribulin mesylate 3 (1.8)
Ixabepilone 3 (1.8)
Cisplatin with docetaxel 2 (1.2)
Cyclophosphamide with docetaxel/doxorubicin 2 (1.2)
Cyclophosphamide with epirubicin hydrochloride/fluorouracil 2 (1.2)
Cyclophosphamide with fluorouracil/methotrexate 2 (1.2)
Doxorubicin hydrochloride 2 (1.2)
Onartuzumab 2 (1.2)
Veliparib 2 (1.2)
PI3 kinase inhibitor 2 (1.2)
Doxorubicin/cyclophosphamide and paclitaxel 1 (0.6)
Carboplatin with gemcitabine 1 (0.6)
Cetuximab 1 (0.6)
5-Fluorouracil, epirubicin, and cyclophosphamide 1 (0.6)
Cyclophosphamide with epirubicin/fluorouracil 1 (0.6)
Epirubicin hydrochloride 1 (0.6)
Idarubicin 1 (0.6)
Irinotecan 1 (0.6)
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Table 7  (continued) Adverse event, n (%) Patients (N = 168)
Any grade Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Edema peripheral 15 (8.9) 8 (4.8) 6 (3.6) 1 (0.6) 0 0
Headache 15 (8.9) 13 (7.7) 2 (1.2) 0 0 0
Elevated AST 14 (8.3) 2 (1.2) 6 (3.6) 6 (3.6) 0 0
Influenza-like illness 14 (8.3) 13 (7.7) 1 (0.6) 0 0 0
Pain in extremity 13 (7.7) 5 (3.0) 5 (3.0) 3 (1.8) 0 0
Disease progression 12 (7.1) 0 0 1 (0.6) 1 (0.6) 10 (6.0)
Musculoskeletal pain 12 (7.1) 4 (2.4) 8 (4.8) 0 0 0
Noncardiac chest pain 12 (7.1) 4 (2.4) 3 (1.8) 5 (3.0) 0 0
Abdominal distension 11 (6.5) 6 (3.6) 4 (2.4) 1 (0.6) 0 0
Anxiety 11 (6.5) 6 (3.6) 5 (3.0) 0 0 0
Decreased weight 11 (6.5) 7 (4.2) 4 (2.4) 0 0 0
Dizziness 11 (6.5) 7 (4.2) 3 (1.8) 1 (0.6) 0 0
Elevated ALT 11 (6.5) 6 (3.6) 4 (2.4) 1 (0.6) 0 0
Hypertension 11 (6.5) 4 (2.4) 5 (3.0) 2 (1.2) 0 0
Insomnia 11 (6.5) 6 (3.6) 5 (3.0) 0 0 0
Musculoskeletal chest pain 11 (6.5) 7 (4.2) 3 (1.8) 1 (0.6) 0 0
Hypothyroidism 10 (6.0) 2 (1.2) 8 (4.8) 0 0 0
Muscle spasms 10 (6.0) 10 (6.0) 0 0 0 0
Neck pain 10 (6.0) 4 (2.4) 6 (3.6) 0 0 0
Dry skin 9 (5.4) 8 (4.8) 1 (0.6) 0 0 0
Hypokalemia 9 (5.4) 3 (1.8) 5 (3.0) 0 1 (0.6) 0
Pruritus 9 (5.4) 7 (4.2) 2 (1.2) 0 0 0
Chest pain 8 (4.8) 5 (3.0) 2 (1.2) 1 (0.6) 0 0
Elevated blood alkaline phosphatase 7 (4.2) 2 (1.2) 3 (1.8) 2 (1.2) 0 0
Myalgia 7 (4.2) 6 (3.6) 0 1 (0.6) 0 0
Elevated GGT 6 (3.6) 1 (0.6) 1 (0.6) 2 (1.2) 2 (1.2) 0
Flank pain 5 (3.0) 2 (1.2) 2 (1.2) 1 (0.6) 0 0
Hyponatremia 5 (3.0) 2 (1.2) 1 (0.6) 2 (1.2) 0 0
Hypoxia 5 (3.0) 0 3 (1.8) 2 (1.2) 0 0
Pneumonia 5 (3.0) 0 1 (0.6) 4 (2.4) 0 0
Hypercalcemia 4 (2.4) 2 (1.2) 1 (0.6) 0 1 (0.6) 0
Thrombocytopenia 4 (2.4) 1 (0.6) 0 0 3 (1.8) 0
Respiratory failure 4 (2.4) 0 0 0 2 (1.2) 2 (1.2)
Autoimmune hepatitis 3 (1.8) 0 0 3 (1.8) 0 0
Axillary pain 3 (1.8) 1 (0.6) 1 (0.6) 1 (0.6) 0 0
General physical health deterioration 3 (1.8) 0 0 2 (1.2) 0 1 (0.6)
Hyperglycemia 3 (1.8) 0 2 (1.2) 1 (0.6) 0 0
Lymphocyte count decreased 3 (1.8) 0 2 (1.2) 1 (0.6) 0 0
Metastatic pain 3 (1.8) 1 (0.6) 0 2 (1.2) 0 0
Pleuritic pain 3 (1.8) 1 (0.6) 1 (0.6) 1 (0.6) 0 0
Pneumonitis 3 (1.8) 1 (0.6) 1 (0.6) 1 (0.6) 0 0
Pneumothorax 3 (1.8) 1 (0.6) 1 (0.6) 1 (0.6) 0 0
Proteinuria 3 (1.8) 2 (1.2) 0 1 (0.6) 0 0
Sinus tachycardia 3 (1.8) 1 (0.6) 1 (0.6) 1 (0.6) 0 0
Atrial fibrillation 2 (1.2) 0 0 1 (0.6) 1 (0.6) 0
Cardiac tamponade 2 (1.2) 0 0 1 (0.6) 1 (0.6) 0
Deep vein thrombosis 2 (1.2) 0 1 (0.6) 1 (0.6) 0 0
Hematuria 2 (1.2) 1 (0.6) 0 1 (0.6) 0 0
Hepatomegaly 2 (1.2) 1 (0.6) 0 1 (0.6) 0 0
Hypophosphatemia 2 (1.2) 0 0 2 (1.2) 0 0
International normalized ratio increased 2 (1.2) 1 (0.6) 0 1 (0.6) 0 0
Jugular vein thrombosis 2 (1.2) 0 0 2 (1.2) 0 0
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Table 7  (continued) Adverse event, n (%) Patients (N = 168)
Any grade Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Metastases to meninges 2 (1.2) 0 1 (0.6) 0 1 (0.6) 0
Neutrophil count decreased 2 (1.2) 1 (0.6) 0 1 (0.6) 0 0
Platelet count decreased 2 (1.2) 0 1 (0.6) 1 (0.6) 0 0
Radiation pneumonitis 2 (1.2) 1 (0.6) 0 1 (0.6) 0 0
Rash papular 2 (1.2) 1 (0.6) 0 1 (0.6) 0 0
Respiratory distress 2 (1.2) 0 0 1 (0.6) 0 1 (0.6)
Acute hepatic failure 1 (0.6) 0 0 0 0 1 (0.6)
Acute kidney injury 1 (0.6) 0 0 1 (0.6) 0 0
Ataxia 1 (0.6) 0 0 1 (0.6) 0 0
Bile duct obstruction 1 (0.6) 0 0 1 (0.6) 0 0
Brain injury 1 (0.6) 0 0 0 0 1 (0.6)
Bronchial obstruction 1 (0.6) 0 0 1 (0.6) 0 0
Burning sensation 1 (0.6) 0 0 1 (0.6) 0 0
Cardiac arrest 1 (0.6) 0 0 0 1 (0.6) 0
Cardiac failure 1 (0.6) 0 0 0 1 (0.6) 0
Cardio-respiratory arrest 1 (0.6) 0 0 0 0 1 (0.6)
Cellulitis 1 (0.6) 0 0 1 (0.6) 0 0
Cholestasis 1 (0.6) 0 0 1 (0.6) 0 0
Coccydynia 1 (0.6) 0 0 1 (0.6) 0 0
Dental caries 1 (0.6) 0 0 1 (0.6) 0 0
Electrocardiogram QT prolonged 1 (0.6) 0 0 1 (0.6) 0 0
Elevated blood potassium 1 (0.6) 0 0 1 (0.6) 0 0
Elevated hepatic enzyme 1 (0.6) 0 0 1 (0.6) 0 0
Failure to thrive 1 (0.6) 0 0 1 (0.6) 0 0
Hemoptysis 1 (0.6) 0 0 1 (0.6) 0 0
Hepatic encephalopathy 1 (0.6) 0 0 0 1 (0.6) 0
Hepatic failure 1 (0.6) 0 0 0 0 1 (0.6)
Hyperbilirubinemia 1 (0.6) 0 0 1 (0.6) 0 0
Hypercalcemia of malignancy 1 (0.6) 0 0 0 1 (0.6) 0
Hypertriglyceridemia 1 (0.6) 0 0 1 (0.6) 0 0
Infection 1 (0.6) 0 0 1 (0.6) 0 0
Liver disorder 1 (0.6) 0 0 1 (0.6) 0 0
Malignant neoplasm progression 1 (0.6) 0 0 0 0 1 (0.6)
Malignant pleural effusion 1 (0.6) 0 0 1 (0.6) 0 0
Malnutrition 1 (0.6) 0 0 1 (0.6) 0 0
Metastases to peripheral nervous system 1 (0.6) 0 0 0 1 (0.6) 0
Monoparesis 1 (0.6) 0 0 1 (0.6) 0 0
Myelodysplastic syndrome 1 (0.6) 0 0 0 1 (0.6) 0
Neutropenia 1 (0.6) 0 0 0 1 (0.6) 0
Obstructive uropathy 1 (0.6) 0 0 1 (0.6) 0 0
Pain in hip, back, and right lower leg 1 (0.6) 0 0 1 (0.6) 0 0
Paraparesis 1 (0.6) 0 0 0 1 (0.6) 0
Pathological fracture 1 (0.6) 0 0 1 (0.6) 0 0
Pleural fistula 1 (0.6) 0 0 1 (0.6) 0 0
Pulmonary arterial hypertension 1 (0.6) 0 0 1 (0.6) 0 0
Pulmonary embolism 1 (0.6) 0 0 0 0 1 (0.6)
Pulmonary hypertension 1 (0.6) 0 0 0 0 1 (0.6)
Sepsis 1 (0.6) 0 0 0 0 1 (0.6)
Spinal cord compression 1 (0.6) 0 0 1 (0.6) 0 0
Tumor invasion 1 (0.6) 0 0 0 0 1 (0.6)
Tumor pain 1 (0.6) 0 0 1 (0.6) 0 0
ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transferase
684 Breast Cancer Res Treat (2018) 167:671–686
1 3
Table 8  Potential immune-
related, treatment-related 
adverse events by grade
The numbers in bold are the total number of immune related evens according to grade
ANA antinuclear antibody
a Autoimmune hepatitis temporarily resolved with steroid treatment, but led to discontinuation in two 
patients; the third patient who experienced autoimmune hepatitis died of acute liver failure in a setting of 
progressive liver metastasis
b Pemphigoid resolved following drug interruption but ultimately led to treatment discontinuation
Adverse event, n (%) Patients (N = 168)
Any grade Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Any event, n (%) 17 (10.1) 4 (2.4) 9 (5.4) 3 (1.8) 1 (0.6) 0
Hypothyroidism 8 (4.8) 1 (0.6) 7 (4.2) 0 0 0
Autoimmune  hepatitisa 3 (1.8) 0 0 3 (1.8) 0 0
Pneumonitis 3 (1.8) 1 (0.6) 1 (0.6) 1 (0.6) 0 0
Thrombocytopenia 2 (1.2) 1 (0.6) 0 0 1 (0.6) 0
ANA positive 1 (0.6) 1 (0.6) 0 0 0 0
Dry eye 1 (0.6) 1 (0.6) 0 0 0 0
Elevated rheumatoid factor 1 (0.6) 1 (0.6) 0 0 0 0
Hyperthyroidism 1 (0.6) 1 (0.6) 0 0 0 0
Pemphigoidb 1 (0.6) 0 1 (0.6) 0 0 0
Table 9  Confirmed ORR by 
subgroup
ECOG PS Eastern Cooperative Oncology Group performance status, ER estrogen receptor, HER2 human 
epidermal growth factor receptor 2, N1 number of evaluable patients, ORR objective response rate, PR pro-
gesterone receptor, TNBC triple-negative breast cancer, N1 number of evaluable patients
a Regimen for locally advanced/metastatic disease may have included hormonal therapy, either alone or in 
combination with chemotherapy. Systemic therapies that were not necessarily cytotoxic are included in the 
number of prior regimens reported here, but the number of cytotoxic therapies permitted was ≤ 3
b Unknown molecular subtype was due to incomplete information in the medical records database (ER/
PR status known, but HER2 status unknown in four patients) or to information collected retrospectively 
(molecular subtype status was from post-baseline samples in eight patients and, therefore, was not used for 
baseline characterization
Subgroup n/N1 ORR % (95% CI)
Age (years)
 < 65 4/140 2.9 (0.8, 7.2)
 ≥ 65 1/28 3.6 (0.1, 18.3)
Race
 White 3/143 2.1 (0.4, 6.0)
 Black 2/25 8.0 (1.0, 26.0)
ECOG
 0 3/83 3.6 (0.8, 10.2)
 ≥ 1 2/85 2.4 (0.3, 8.2)
Prior lines for metastatic  diseasea
 ≤ 1 2/45 4.4 (0.5, 15.1)
 2 2/35 5.7 (0.7,19.2)
 ≥ 3 1/88 1.1 (0, 6.2)
Biomarker group
 TNBC 3/58 5.2 (1.1, 14.4)
 HER2− (ER+ or PR+) 2/72 2.8 (0.3, 9.7)
 HER2+ 0/26 0 (0, 13.2)
 Unknownb 0/12 0 (0, 26.5)
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